Land: Armenien
Sprog: engelsk
Kilde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
diclofenac (diclofenac diethylamine)
Novartis Consumer Health S.A.
M02AA15
diclofenac (diclofenac diethylamine)
20mg/g
gel for external use
50g laminated tube, 100g laminated tube
OTC
Registered
2015-09-04
I
Bo.ru.rnpeH 3Mym.reJib
2%
renT>
p,!ISI
Hapy?KHoro
npHMeHeHHSI,
JIHCTOR- BlOPM~M.5I
,ZVI5I
ITA~MEHTOB)
TOPROSOE UA3SAUUENPENAPATA:
BOllhTAPE~
3MYnhrEnh®
ME)KJ.EYLLAPO,!L;UOE
UENATEHTOBAUUOE UA3BANUE:
.D:HKJioeuru<
JLEKAPCMEUUAN
C}JOPMA:
reJII,
.n;JUI
uapy)KHoro npHMeuemm
2%
COCTAB:
B
1
r npenapaTa
co.n;ep)I(HTC51:
BY
AKTUBHOE
BEM:ECTBO:
23,2Mr
,!I;HKJIOeHrueHruHH
)KH)l;KHH,
OJieHJIOBhiH
CUHp
T,
3BKaJIHITTOBa51
QT.n;ymKa,
6yTHJirH.n;pOKCHTOJIYOJI,
npOITHJieHrJIHKOJih,
BO)l;a
QqHII.(eHHM:
ONUCAUUE:
M51rKHH,
o.n;uopo.n;Hhlii,
KpeMoo6pa3Hhili reJih,
[(BeT
oT
6enoro
.!1:0
)l(eJITosaroro.
«J)APMAKOTEPANEBTUQECKAB
RPYNNA
Cpe.n;crsa
.
.n;Jl51
Hapy)KHoro
npHMeHeHH51
npH
6oJI5~X
B cycrasax H Mhiiiii.(ax.
HecrepoH.n;Hbie
npomsosocnanHTeJihHhie
cpe.n.crsa
.n;AA
Hap)')I(Horo
npHMeHeHH51.
KO).L.
ATX:
M02AA15
«J)APMAKOJIORUQECKUCCBOHCTBA
WAPMAKOTJ:HHAMUKA
,[{HKJioeHru<
uecrepoH.n;uoe
npoTHBopesMarHqecKoe
cpe.n;crno
c
Bhipa)l(eHHbiM
aHanbrern:qecKHM,
npoTHBOBOCITaJIHTeJihHhiM
H
:aeHrueuaKa,
scacbmaiOmeroc5~
qepe3
Ko~,
nponopuHoHaJibHO
nnoma.n:u
o6pa6arhmaeMoii
nosepxuocrH
H
3aBHCHT
I~
JJ;O~!?lJlaHOCRMO
npenapara,
Ta.K
H .
OT
CTeUeHH
m.n;paTffilHH
I
Læs hele dokumentet
Novartis Consumer Health SA CH-1260 Nyon, Switzerland Global Regulatory Affairs VOLTAREN ®EMULGEL® Gel Diclofenac diethylamine 2.32% F.AADI01 REGIONAL SUMMARY OF PRODUCT CHARACTERISTICS (SMPC) Property of Novartis Consumer Health Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis Consumer Health Novartis Consumer Health SA CONFIDENTIAL Page 2 EU-rSmPC Voltaren Forte 2.32% gel TABLE OF CONTENTS 1 NAME OF THE MEDICINAL PRODUCT ....................................................................... 3 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ............................................. 3 3 PHARMACEUTICAL FORM ............................................................................................ 3 4 CLINICAL PARTICULARS .............................................................................................. 3 4.1 Therapeutic indications ............................................................................................ 3 4.2 Posology and method of administration .................................................................. 3 4.3 Contraindications ..................................................................................................... 4 4.4 Special warnings and precautions for use ................................................................ 5 4.5 Interaction with other medicinal products and other forms of interaction .............. 5 4.6 Pregnancy and lactation ........................................................................................... 5 4.7 Effects on ability to drive and use machines ........................................................... 5 4.8 Undesirable effects .................................................................................................. 5 4.9 Overdose .................................................................................................................. 6 5 PHARMACOLOGICAL PROPERTIES ............................................................................ 6 Læs hele dokumentet